Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.

doi:10.1245/s10434-011-2120-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.

Annals of surgical oncology - 1 May 2012

Italiano Antoine, Cioffi Angela, Coco Paola, Maki Robert G, Schöffski Patrick, Rutkowski Piotr, Le Cesne Axel, Duffaud Florence, Adenis Antoine, Isambert Nicolas, Bompas Emmanuelle, Blay Jean-Yves, Casali Paolo, Keohan Mary Louise, Toulmonde Maud, Antonescu Cristina R, Debiec-Rychter Maria, Coindre Jean-Michel, Bui Binh

Abstract excerpt

BACKGROUND: Data regarding the management and outcome of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to 1st-line imatinib and 2nd-line sunitinib are limited. METHODS: Medical records of 223 imatinib-resistant and sunitinib-resistant GIST who were treated in 11 major referral centers were reviewed. RESULTS: The three most frequent drugs used in the 3rd-line setting were: nilotinib n...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Serum Albumin

Share to Sorafenib

Share to Sunitinib

Source

Open in PubMed

Identifiers

PMID: 22065192
DOI: 10.1245/s10434-011-2120-6

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.PMID 22065192Read ↗

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability.Semantic proximity Read ↗

Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.Semantic proximity Read ↗

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment.Semantic proximity Read ↗

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.Semantic proximity Read ↗

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.Semantic proximity Read ↗

Efficacy evaluation of nilotinib treatment in different genomic subtypes of gastrointestinal stromal tumors: A meta-analysis and systematic review.Semantic proximity Read ↗

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Semantic proximity Read ↗

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.Semantic proximity Read ↗

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.Semantic proximity Read ↗

Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.